Navigation Links
Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
Date:10/27/2008

venue of 3.6 billion euro in 2007. UCB is listed on NYSE Euronext (symbol: UCB). Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Ga. For more information about UCB, visit http://www.ucb-group.com.

Forward-Looking Statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... and HENDERSONVILLE, N.C. , ... bidding procurement program for home medical equipment is ... North Carolina to lay off employees or ... quality of service and products received by Medicare beneficiaries, ... the defective and dangerous program, the Centers for ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... ABBOTT PARK, Ill., Nov. 12 Nearly one in three ... and nearly 34 million have low HDL "good" cholesterol levels. ... and trigs, Abbott has launched two Web sites: ... "Unhealthy high triglyceride and low HDL levels are factors that ...
... IRVINE, Calif., Nov. 12 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, and CareFusion ... device company, today announced a multi-year technology licensing ... capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology ...
Cached Medicine Technology:New Web Sites Educate About Triglycerides and HDL Cholesterol 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 3CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 4
(Date:5/21/2013)... Gray HealthDay Reporter , , TUESDAY, May 21 ... was once next to impossible, but a new study ... screening with low-dose CT scans may help spot the ... patients considered at the greatest risk for lung cancer, ... getting CT scans and follow-up biopsies to confirm the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Pathways ... who are grieving to remember and honor a loved ... of Remembrance Memorial Service, Sunday, June 2, 2013, 3-4 ... Boulevard, San Mateo, CA 94402. , The Pathways ... includes a short program with music, readings and support. ...
(Date:5/21/2013)... 2013 Not all treatments are effective ... Borderline Personality Disorder (BPD) and addiction. Dialectical Behavior Therapy ... successful for the treatment of both BPD and substance ... Ph.D., clinical director of Clearview Women’s Center for ... provide attendees of the West Coast Symposium on Addictive ...
(Date:5/21/2013)... obese patients are significantly more likely than their ... a practice that disrupts continuity of care and ... Hopkins research suggests. , The practice of "doctor ... of negative experiences with the health care system, ... unsolicited weight loss advice by providers, or improperly ...
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
Breaking Medicine News(10 mins):Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3Health News:Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2
... dedicated to the health and well being of children, ... (FDA) has approved an investigational new drug application; ... topical solution for the treatment of head lice. ... professionals a new choice for the treatment of head ...
... cyclists will be participating in the Memory Ride for Alzheimer's ... to fight the disease that affects more than 5 ... 11th annual Memory Ride has a personal story to tell ... who has struggled with the disease. ,The Alzheimer's ...
... is not as squeaky-clean as she appears . ,In a ... she is quite the opposite of her supposed righteous image. ... Do you think you have a squeaky-clean image? Im like, Could ... Us Weekly quoted her, as telling the mag. ,I ...
... the University of Idaho is helping to increase understanding ... identify conditions that make women prone to infections and ... problems. ,Women suffer from insidious health problems, ... send them in droves to seek medical treatment, said ...
... the occurrence of anaphylaxis between the northern and southern ... be fatal without treatment with epinephrine. The striking ... risk, currently are without explanation. The investigators hypothesize, however, ... sunshine, may play a role and that this hypothesis ...
... can relieve people of shyness, and help them socialise with ... use, and an individual can boost self-confidence just by squirting ... that the spray harnesses the powers of a feel-good hormone ... in social recognition and bonding. ,The mammalian ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Large Geographic Differences in EpiPen Prescriptions in the U. S. 2
... comfortable eye protection Properly manufactured radiation ... scatter radiation. Our high quality frames and ... with minimized weight. Our lenses are made ... meet all industry standards. Most Pulse Glasses ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
Medicine Products: